Madrigal Pharmaceuticals
MDGL
137 hedge funds and large institutions have $1.43B invested in Madrigal Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 53 increasing their positions, 37 reducing their positions, and 16 closing their positions.
137% more call options, than puts
Call options by funds: $8.08M | Put options by funds: $3.41M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 37
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
4% more funds holding
Funds holding: 132 → 137 (+5)
5% more capital invested
Capital invested by funds: $1.36B → $1.43B (+$63.5M)
3.16% less ownership
Funds ownership: 79.34% → 76.17% (-3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24.8M |
| 2 |
Morgan Stanley
New York
|
+$24.6M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$23.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.8M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$100M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$37.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.99M |
| 5 |
State Street
Boston,
Massachusetts
|
-$6.72M |
MDGL Hedge Fund Activity: Q1 2021 in Review
137 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2021, worth a combined $1.43B — up 4.7% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MDGL positions and 16 closed out — a net gain of 5 holders — while 53 added to existing stakes and 37 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $24.8M. The largest seller was HealthCor Management, exiting entirely with an estimated $100M sold.
- 137 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2021, up from 132 in Q4 2020.
- Funds reported $1.43B of Madrigal Pharmaceuticals stock for Q1 2021, up 4.7% quarter-over-quarter.
- 21 funds opened new Madrigal Pharmaceuticals positions in Q1 2021 and 16 closed out, a net change of +5 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2021 was Citadel Advisors, an estimated $24.8M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2021 was HealthCor Management, an estimated $100M sold.
Based on aggregated 13F filings for Q1 2021.